Field Medical, a leader in cardiac ablation technology, has announced the commencement of its groundbreaking first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. This study, known as the Ventricular Catheter Ablation Study (VCAS), aims to enroll up to 60 patients at multiple sites worldwide.
The FieldForce™ Ablation System is a contact force pulsed field ablation (PFA) catheter that has been specifically designed to address the limitations of existing PFA and radiofrequency (RF) ablation systems. This innovative technology offers a more time-efficient treatment protocol for ventricular arrhythmias, providing highly targeted treatment options and improving workflow efficiency.
“The FieldForce Ablation System is demonstrating significant promise early in our trials,” said Dr. Vivek Reddy, Director of Electrophysiology for the Mount Sinai Health System. “This technology has the potential to revolutionize the treatment of complex ventricular arrhythmias, surpassing the current standard of care.”
PFA technology has already revolutionized the treatment of atrial fibrillation (AF), thanks to the pioneering work of Field Medical CEO Dr. Steven Mickelsen. The success of PFA in atrial settings has led to widespread adoption and transformed ablation practices. Now, Field Medical aims to extend these benefits to ventricular arrhythmias, a condition that affects over 6 million patients in the US and Europe.
Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation. The FieldForce™ Ablation System seeks to address these challenges by providing an optimized contact force PFA catheter that works in the ventricles. This novel technology offers a predictable, time-efficient, and safe treatment option for patients with ventricular arrhythmias.
Through the VCAS study, Field Medical aims to demonstrate the safety and performance of the FieldForce™ Ablation System, with the ultimate goal of transforming ventricular arrhythmia ablation into a widely-available, one-hour outpatient procedure with improved safety outcomes. With strong investor support and the groundbreaking potential of their technology, Field Medical is set to redefine the standards of cardiac ablation once again.
For more information about the VCAS study and Field Medical’s innovative technologies, visit www.fieldmedicalinc.com.
Field Medical’s first-in-human study for the FieldForce™ Ablation System aims to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems in the treatment of ventricular arrhythmias. This innovative technology offers a more time-efficient treatment protocol and improved workflow efficiency for patients with ventricular arrhythmias. Dr. Vivek Reddy, Director of Electrophysiology for the Mount Sinai Health System, has noted that the FieldForce Ablation System has the potential to revolutionize the treatment of complex ventricular arrhythmias, surpassing the current standard of care.
PFA technology has already made significant advancements in the treatment of atrial fibrillation (AF), thanks to the pioneering work of Field Medical CEO Dr. Steven Mickelsen. The success of PFA in atrial settings has led to its widespread adoption and transformed ablation practices. Field Medical now aims to extend these benefits to ventricular arrhythmias, which affect over 6 million patients in the US and Europe.
The current methods of ventricular catheter ablation involve lengthy procedures and significant risks associated with thermal ablation. The FieldForce™ Ablation System seeks to address these challenges by providing an optimized contact force PFA catheter that works specifically in the ventricles. This novel technology offers a predictable, time-efficient, and safe treatment option for patients with ventricular arrhythmias.
Field Medical’s VCAS study aims to demonstrate the safety and performance of the FieldForce™ Ablation System. The ultimate goal is to transform ventricular arrhythmia ablation into a widely-available, one-hour outpatient procedure with improved safety outcomes. With strong investor support and the groundbreaking potential of their technology, Field Medical is poised to redefine the standards of cardiac ablation once again.
Some key advantages of the FieldForce™ Ablation System include its ability to provide highly targeted treatment options for ventricular arrhythmias, improve workflow efficiency, and potentially revolutionize the treatment of complex cases. By offering a predictable, time-efficient, and safe treatment option, this technology has the potential to significantly improve patient outcomes.
However, it is important to consider potential disadvantages or challenges associated with the FieldForce™ Ablation System. As this is a first-in-human study, further research is needed to fully evaluate the long-term safety and effectiveness of the system. Additionally, widespread adoption and implementation of the technology may require significant investment and changes to current clinical practices.
For more information about the VCAS study and Field Medical’s innovative technologies, you can visit their website at www.fieldmedicalinc.com.